Elekta
- Home ›
- SE ›
- Healthcare
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The last earnings update was 84 days ago. More info.
Add to Portfolio Compare Print
EKTA B Share Price and Events
7 Day Returns
1 Year Returns
EKTA B Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Elekta (EKTA B) | 1.3% | 7.7% | 25.8% | 69.9% | 77.4% | 51.3% |
| SE Medical Equipment | 3% | 14.9% | 18.4% | 38.8% | 23% | -4.3% |
| SE Market | 2.3% | 6.2% | 9.3% | 1.6% | 16.2% | 18.9% |
1 Year Return vs Industry and Market
- EKTA B outperformed the Medical Equipment industry which returned 38.8% over the past year.
- EKTA B outperformed the Market in Sweden which returned 1.6% over the past year.
EKTA B Value
Is Elekta undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Elekta
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Elekta.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 14 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.1% |
| Perpetual Growth Rate | 10-Year SE Government Bond Rate | 0.4% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year SE Govt Bond Rate | 0.4% |
| Equity Risk Premium | S&P Global | 9.6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.75 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.747 (1 + (1- 22%) (10.03%)) |
0.806 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.81 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.43% + (0.806 * 9.57%) |
8.14% |
Discounted Cash Flow Calculation for OM:EKTA B using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Elekta is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (SEK, Millions) | 1,343.87 | 1,768.28 | 2,164.90 | 2,160.00 | 2,368.50 |
| Source | Analyst x7 | Analyst x9 | Analyst x7 | Analyst x2 | Analyst x2 |
|
Present Value Discounted (@ 8.14%) |
1,242.71 | 1,512.08 | 1,711.88 | 1,579.43 | 1,601.52 |
| Present value of next 5 years cash flows | SEK7,647.63 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= SEK2,368.50 × (1 + 0.43%) ÷ (8.14% – 0.43%) |
SEK30,868.81 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= SEK30,868.81 ÷ (1 + 8.14%)5 |
SEK20,872.75 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= SEK7,647.63 + SEK20,872.75 |
SEK28,520.38 |
| Equity Value per Share (SEK) |
= Total value / Shares Outstanding
= SEK28,520.38 / 382.03 |
SEK74.66 |
| Calculation | Result | |
|---|---|---|
| Value per share (SEK) | From above. | SEK74.66 |
| Current discount | Discount to share price of
SEK129.40
= -1 x (SEK129.40 - SEK74.66) / SEK74.66 |
-73.3% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Elekta is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Elekta's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Elekta's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-10-31) in SEK | SEK2.74 |
| OM:EKTA B Share Price ** | OM (2019-02-21) in SEK | SEK129.4 |
| Sweden Medical Equipment Industry PE Ratio | Median Figure of 12 Publicly-Listed Medical Equipment Companies | 37.81x |
| Sweden Market PE Ratio | Median Figure of 322 Publicly-Listed Companies | 16.21x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Elekta.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = OM:EKTA B Share Price ÷ EPS (both in SEK) = 129.4 ÷ 2.74 |
47.26x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Elekta is overvalued based on earnings compared to the SE Medical Equipment industry average.
- Elekta is overvalued based on earnings compared to the Sweden market.
Price based on expected Growth
Does
Elekta's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 47.26x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts |
17%per year |
| Sweden Medical Equipment Industry PEG Ratio | Median Figure of 8 Publicly-Listed Medical Equipment Companies | 2.59x |
| Sweden Market PEG Ratio | Median Figure of 228 Publicly-Listed Companies | 1.2x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 47.26x ÷ 17% |
2.79x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Elekta is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Elekta's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-10-31) in SEK | SEK18.24 |
| OM:EKTA B Share Price * | OM (2019-02-21) in SEK | SEK129.4 |
| Sweden Medical Equipment Industry PB Ratio | Median Figure of 42 Publicly-Listed Medical Equipment Companies | 4.29x |
| Sweden Market PB Ratio | Median Figure of 561 Publicly-Listed Companies | 2.43x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = OM:EKTA B Share Price ÷ Book Value per Share (both in SEK) = 129.4 ÷ 18.24 |
7.09x |
* Primary Listing of Elekta.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Elekta is overvalued based on assets compared to the SE Medical Equipment industry average.
Value checks
We assess Elekta's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Elekta has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
EKTA B Future Performance
How is Elekta expected to perform in the next 1 to 3 years based on estimates from 14 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Elekta's earnings growth is expected to exceed the low risk savings rate of 0.4%.
Growth vs Market Checks
- Elekta's earnings growth is expected to exceed the Sweden market average.
- Elekta's revenue growth is expected to exceed the Sweden market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| OM:EKTA B Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts | 17% |
| OM:EKTA B Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts | 9.2% |
| Sweden Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 31.8% |
| Sweden Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 9.7% |
| Sweden Market Earnings Growth Rate | Market Cap Weighted Average | 8.7% |
| Sweden Market Revenue Growth Rate | Market Cap Weighted Average | 4.6% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 14 Analyst Estimates (S&P Global) | See Below |
| Date (Data in SEK Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-04-30 | 17,637 | 3,401 | 2,130 | 1 |
| 2022-04-30 | 16,673 | 3,142 | 1,993 | 1 |
| 2021-04-30 | 15,950 | 2,884 | 2,046 | 12 |
| 2020-04-30 | 14,362 | 2,447 | 1,618 | 14 |
| 2019-04-30 | 12,964 | 2,101 | 1,332 | 14 |
| Date (Data in SEK Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-10-31 | 12,075 | 2,056 | 1,046 |
| 2018-07-31 | 11,648 | 1,947 | 1,066 |
| 2018-04-30 | 11,333 | 2,404 | 1,099 |
| 2018-01-31 | 11,869 | 2,392 | 905 |
| 2017-10-31 | 11,795 | 2,095 | 639 |
| 2017-07-31 | 11,326 | 2,034 | 389 |
| 2017-04-30 | 10,704 | 1,819 | 125 |
| 2017-01-31 | 10,596 | 1,442 | 108 |
| 2016-10-31 | 10,470 | 1,375 | 70 |
| 2016-07-31 | 10,864 | 1,380 | 203 |
| 2016-04-30 | 11,221 | 1,170 | 137 |
| 2016-01-31 | 11,469 | 1,989 | 402 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 14 Analyst Estimates (S&P Global) | See Below |
All data from Elekta Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in SEK Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-04-30 | 5.57 | 5.57 | 5.57 | 1.00 |
| 2022-04-30 | 5.22 | 5.22 | 5.22 | 1.00 |
| 2021-04-30 | 5.34 | 6.98 | 4.00 | 8.00 |
| 2020-04-30 | 4.21 | 4.86 | 3.48 | 11.00 |
| 2019-04-30 | 3.46 | 3.71 | 2.97 | 11.00 |
| Date (Data in SEK Millions) | EPS * |
|---|---|
| 2018-10-31 | 2.74 |
| 2018-07-31 | 2.79 |
| 2018-04-30 | 2.88 |
| 2018-01-31 | 2.37 |
| 2017-10-31 | 1.67 |
| 2017-07-31 | 1.02 |
| 2017-04-30 | 0.33 |
| 2017-01-31 | 0.28 |
| 2016-10-31 | 0.18 |
| 2016-07-31 | 0.53 |
| 2016-04-30 | 0.36 |
| 2016-01-31 | 1.05 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Elekta's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Elekta has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
EKTA B Past Performance
How has Elekta performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Elekta's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Elekta's 1-year earnings growth exceeds its 5-year average (63.7% vs -10.5%)
- Elekta's earnings growth has exceeded the SE Medical Equipment industry average in the past year (63.7% vs 21.9%).
Earnings and Revenue History
All data from Elekta Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in SEK Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-10-31 | 12,075.00 | 1,046.00 | 2,229.00 | 1,273.00 |
| 2018-07-31 | 11,648.00 | 1,066.00 | 2,197.00 | 1,144.00 |
| 2018-04-30 | 11,333.00 | 1,099.00 | 2,156.00 | 1,095.00 |
| 2018-01-31 | 11,869.00 | 905.00 | 2,137.00 | 1,147.00 |
| 2017-10-31 | 11,795.00 | 639.00 | 2,129.00 | 1,144.00 |
| 2017-07-31 | 11,326.00 | 389.00 | 2,150.00 | 1,083.00 |
| 2017-04-30 | 10,704.00 | 125.00 | 2,093.00 | 1,018.00 |
| 2017-01-31 | 10,596.00 | 108.00 | 2,139.00 | 977.00 |
| 2016-10-31 | 10,470.00 | 70.00 | 2,200.00 | 991.00 |
| 2016-07-31 | 10,864.00 | 203.00 | 2,238.00 | 1,044.00 |
| 2016-04-30 | 11,221.00 | 137.00 | 2,362.00 | 1,065.00 |
| 2016-01-31 | 11,469.00 | 402.00 | 2,548.00 | 1,070.00 |
| 2015-10-31 | 11,474.00 | 548.00 | 2,526.00 | 1,022.00 |
| 2015-07-31 | 11,213.00 | 558.00 | 2,485.00 | 974.00 |
| 2015-04-30 | 10,839.00 | 552.00 | 2,383.00 | 952.00 |
| 2015-01-31 | 10,938.00 | 1,029.00 | 2,097.00 | 904.00 |
| 2014-10-31 | 10,771.00 | 1,026.00 | 2,027.00 | 902.00 |
| 2014-07-31 | 10,647.00 | 1,017.00 | 1,999.00 | 896.00 |
| 2014-04-30 | 10,694.00 | 1,148.00 | 1,974.00 | 866.00 |
| 2014-01-31 | 10,471.00 | 1,173.00 | 1,964.00 | 805.00 |
| 2013-10-31 | 10,514.00 | 1,256.00 | 1,993.00 | 778.00 |
| 2013-07-31 | 10,556.00 | 1,322.00 | 2,019.00 | 736.00 |
| 2013-04-30 | 10,339.00 | 1,340.00 | 2,025.00 | 715.00 |
| 2013-01-31 | 9,727.00 | 1,041.00 | 2,039.00 | 736.00 |
| 2012-10-31 | 9,864.00 | 1,201.00 | 2,023.00 | 690.00 |
| 2012-07-31 | 9,315.00 | 1,192.00 | 1,936.00 | 664.00 |
| 2012-04-30 | 9,048.00 | 1,227.00 | 1,838.00 | 604.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Elekta has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Elekta used its assets less efficiently than the SE Medical Equipment industry average last year based on Return on Assets.
- Elekta has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Elekta's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Elekta has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
EKTA B Health
How is Elekta's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Elekta's finances.
The net worth of a company is the difference between its assets and liabilities.
- Elekta is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Elekta's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Elekta Company Filings, last reported 3 months ago.
| Date (Data in SEK Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-10-31 | 6,970.00 | 4,958.00 | 3,669.00 |
| 2018-07-31 | 6,843.00 | 4,854.00 | 3,547.00 |
| 2018-04-30 | 7,975.00 | 5,344.00 | 4,541.00 |
| 2018-01-31 | 7,040.00 | 5,063.00 | 3,612.00 |
| 2017-10-31 | 6,734.00 | 5,149.00 | 3,214.00 |
| 2017-07-31 | 6,511.00 | 5,071.00 | 3,158.00 |
| 2017-04-30 | 6,774.00 | 5,272.00 | 3,383.00 |
| 2017-01-31 | 6,422.00 | 5,130.00 | 2,284.00 |
| 2016-10-31 | 6,581.00 | 5,180.00 | 2,121.00 |
| 2016-07-31 | 6,529.00 | 5,092.00 | 2,060.00 |
| 2016-04-30 | 6,412.00 | 4,950.00 | 2,273.00 |
| 2016-01-31 | 6,432.00 | 5,047.00 | 1,683.00 |
| 2015-10-31 | 6,650.00 | 5,041.00 | 1,586.00 |
| 2015-07-31 | 6,835.00 | 6,151.00 | 2,748.00 |
| 2015-04-30 | 6,646.00 | 6,033.00 | 3,265.00 |
| 2015-01-31 | 6,226.00 | 5,036.00 | 1,011.00 |
| 2014-10-31 | 5,847.00 | 4,665.00 | 942.00 |
| 2014-07-31 | 6,357.00 | 4,600.00 | 1,595.00 |
| 2014-04-30 | 6,257.00 | 4,486.00 | 2,247.00 |
| 2014-01-31 | 5,302.00 | 4,499.00 | 1,199.00 |
| 2013-10-31 | 5,056.00 | 4,419.00 | 1,173.00 |
| 2013-07-31 | 5,535.00 | 4,459.00 | 1,826.00 |
| 2013-04-30 | 5,560.00 | 4,552.00 | 2,567.00 |
| 2013-01-31 | 4,756.00 | 4,376.00 | 1,554.00 |
| 2012-10-31 | 4,699.00 | 4,485.00 | 1,589.00 |
| 2012-07-31 | 4,824.00 | 4,545.00 | 1,642.00 |
| 2012-04-30 | 5,010.00 | 4,530.00 | 1,903.00 |
- Elekta's level of debt (71.1%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (87.4% vs 71.1% today).
- Debt is well covered by operating cash flow (41.5%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 15.9x coverage).
Financial health checks
We assess Elekta's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Elekta has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
EKTA B Dividends
What is Elekta's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
SEK2,000 of
Elekta
shares you are expected to receive
SEK22
in your first year as a dividend.
Dividend Amount
- Elekta's pays a lower dividend yield than the bottom 25% of dividend payers in Sweden (1.88%).
- Elekta's dividend is below the markets top 25% of dividend payers in Sweden (4.86%).
Upcoming dividend payment
Purchase Elekta on or before the 'Buy Limit' to receive their next dividend payment.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 14 Analyst Estimates (S&P Global) | See Below |
| Sweden Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 8 Stocks | 1.1% |
| Sweden Market Average Dividend Yield | Market Cap Weighted Average of 244 Stocks | 3.7% |
| Sweden Minimum Threshold Dividend Yield | 10th Percentile | 1.2% |
| Sweden Bottom 25% Dividend Yield | 25th Percentile | 1.9% |
| Sweden Top 25% Dividend Yield | 75th Percentile | 4.9% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in SEK) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-04-30 | 2.50 | 1.00 |
| 2022-04-30 | 2.30 | 1.00 |
| 2021-04-30 | 2.06 | 12.00 |
| 2020-04-30 | 1.73 | 14.00 |
| 2019-04-30 | 1.43 | 14.00 |
| Date (Data in SEK) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2018-08-09 | 1.400 | 1.210 |
| 2018-06-01 | 1.400 | 1.179 |
| 2017-08-23 | 1.000 | 1.241 |
| 2016-08-11 | 0.500 | 0.616 |
| 2016-06-01 | 0.500 | 0.760 |
| 2015-09-01 | 0.500 | 0.794 |
| 2014-08-28 | 2.000 | 2.865 |
| 2013-09-03 | 1.500 | 1.628 |
| 2012-08-06 | 1.250 | 1.286 |
| 2012-04-05 | 1.000 | 1.201 |
| 2011-08-23 | 1.000 | 1.411 |
| 2011-06-09 | 1.000 | 1.459 |
| 2010-08-23 | 0.750 | 1.182 |
| 2009-09-15 | 0.500 | 1.137 |
| 2009-02-23 | 0.438 | 1.703 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Elekta is not paying a notable dividend for Sweden, therefore no need to check if the payments are stable.
- Elekta is not paying a notable dividend for Sweden, therefore no need to check if the payments are increasing.
Income/ dividend checks
We assess Elekta's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Elekta afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Elekta has a total score of 1/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
EKTA B Management
CEO
| COMPENSATION | SEK14,820,000 |
| AGE | 58 |
| TENURE AS CEO | 2.7 years |
CEO Bio
Dr. Richard Hausmann, Ph.D. has been the Chief Executive Officer and President of Elekta AB (publ) since June 10, 2016. Dr. Hausmann has been Vice President at General Electric Company since January 1, 2012. He served as Chief Executive Officer and President of the Global MR Business for GE Healthcare Limited since December 2011 until October 2014. Dr. Hausmann served as General Manager of Magnetic Resonance (MR) Business at GE Healthcare Limited since January 1, 2012. He joined GE Healthcare from Siemens AG Energy. Dr. Hausmann served as Head of Smart Grid Applications at Siemens Aktiengesellschaft and served as its Head of Operations in China since January 1, 2005. He served as the Chief Executive Officer and President of Siemens Ltd., China since January 1, 2005 and also served as its Member of the Management Board. He served as President and Chief Executive Officer of cluster of Siemens North Asia for five years. He has a commercial background in healthcare, serving as President and Chief Executive Officer of the Siemens Healthcare CT business as well as Vice President of Marketing and Sales, CT. Dr. Hausmann was responsible for Siemens Groups Power Generation, Power Transmission and Distribution, Transportation Systems, Medical Solutions as well as the departments Corporate Communication, Strategic Planning & Corporate Development, Government Relations and Corporate Technology. He served as the president and Chief Executive Officer, Computed Tomography for the Siemens Medical Solutions Group and led the Medical Engineering Group as the Vice President of Strategy, Marketing and Sales & Product Planning. He joined Siemens Medical Engineering Group in June 1988. He served in the Applications Development Department of the Magnetic Resonance (MR) Division. until 1993. From 1994 to 1995, Dr. Hausmann served as Marketing Manager for the new Magnetom Open MR system. In 1995, he served as Manager of MR Applications Development and Director for Marketing and Product Planning. He joined the Computer Tomography (CT) Division in 1998, where he served as Division President since April 2000 and was also responsible for the China business of Siemens Medical Solutions Group. Dr. Hausmann served as Head of Siemens Ag's Computer Tomography Division. He published numerous articles on modern applications of Magnetic Resonance and holds various patents related to Magnetic Resonance and Imaging. In 1988, he completed his studies with a Doctorate in Physics at Regensburg University, Germany. Dr. Hausmann studied Physics at the State University of New York at Stony Brook.
CEO Compensation
- Richard's compensation has increased by more than 20% in the past year.
- Richard's remuneration is about average for companies of similar size in Sweden.
Management Team Tenure
Average tenure and age of the Elekta management team in years:
- The average tenure for the Elekta management team is less than 2 years, this suggests a new team.
Management Team
Laurent Leksell
Founder & Chairman
SEK1M
66
Richard Hausmann
President & CEO
SEK15M
58
2.7 yrs
Gustaf Salford
CFO & Executive VP
41
1.6 yrs
Steve Wort
COO & Group VP of Manufacturing & Logistics
55
1.4 yrs
John Lapré
Chief Technology Officer
54
2.8 yrs
Gunilla Öhman
Head of Investor Relations
59
Caroline Mofors
Senior VP
46
4.4 yrs
Jonas Bolander
General Counsel & Executive VP
52
2.3 yrs
Oskar Bosson
Executive Vice President of Corporate Communications & Investor Relations
42
1 yrs
Ioannis Panagiotelis
Chief Marketing & Sales Officer
46
1.5 yrs
Board of Directors Tenure
Average tenure and age of the Elekta board of directors in years:
- The tenure for the Elekta board of directors is about average.
Board of Directors
Laurent Leksell
Founder & Chairman
SEK1M
66
5.4 yrs
Birgitta Göransson
Independent Director
SEK710K
61
14.1 yrs
Tomas Puusepp
Non-Executive Director
SEK7M
63
6.1 yrs
Luciano Cattani
Independent Director
SEK560K
73
10.4 yrs
Jan Secher
Independent Director
SEK620K
61
9.1 yrs
Wolfgang Reim
Independent Director
SEK485K
62
8.1 yrs
Johan Malmquist
Independent Director
SEK560K
57
4.1 yrs
Annika Jansson
Independent Director
SEK620K
54
4.1 yrs
Caroline Cooke
Independent Director
SEK485K
37
1.5 yrs
Cecilia Wikström
Director
53
0.5 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (SEK) | Value (SEK) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 21. Jun 18 | Sell | Laurent Leksell | Individual | 20. Jun 18 | 20. Jun 18 | -800,000 | SEK116.17 | SEK-92,936,002 | ||
Management checks
We assess Elekta's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Elekta has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
EKTA B Company Info
Map
Description
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; microSelectron, a digital pulsed dose rate platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Elekta Neuromag TRIUX, a magnetoencephalography system; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Details
| Name: | Elekta AB (publ) |
| EKTA B | |
| Exchange: | OM |
| Founded: | 1972 |
| SEK49,434,299,105 | |
| 382,027,041 | |
| Website: | http://www.elekta.com |
| Address: |
Elekta AB (publ) Box 7593, Stockholm, Stockholm County, 103 93, Sweden |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| OM | EKTA B | Series B Registered Shares | OMX Nordic Exchange Stockholm | SE | SEK | 02. Mar 1994 | |
| OTCPK | EKTA.F | Series B Registered Shares | Pink Sheets LLC | US | USD | 02. Mar 1994 | |
| DB | EJXB | Series B Registered Shares | Deutsche Boerse AG | DE | EUR | 02. Mar 1994 | |
| LSE | 0O5H | Series B Registered Shares | London Stock Exchange | GB | SEK | 02. Mar 1994 | |
| BATS-CHIXE | EKTABS | Series B Registered Shares | BATS 'Chi-X Europe' | GB | SEK | 02. Mar 1994 | |
| OTCPK | EKTA.Y | UNSPONSOD ADR | Pink Sheets LLC | US | USD | 08. Dec 2008 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/21 20:49 |
| End of day share price update: | 2019/02/21 00:00 |
| Last estimates confirmation: | 2019/02/20 |
| Last earnings filing: | 2018/11/29 |
| Last earnings reported: | 2018/10/31 |
| Last annual earnings reported: | 2018/04/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
